Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 3, 2003, Pages 251-258

  Caramurú, Lúcia Helena ^a   Soares, Rosangela de P S ^b   Maeda, Nair Yukie ^b   Lopes, Antonio Augusto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Pró Sangue Foundation Institute for Investigation in Immunology Iii INCT   (Brazil)

Author keywords

Hypoxia; Platelet; Pulmonary hypertension; Thrombosis; von Willebrand factor

Indexed keywords

BETA THROMBOGLOBULIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTOSIS; HEMATOCRIT; HEMODILUTION; HUMAN; HYPOTHESIS; HYPOXIA; LUNG ARTERY PRESSURE; MOLECULAR WEIGHT; OXYGEN SATURATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PULMONARY HYPERTENSION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 0041328247     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900311     Document Type: Article

References (35)

1. Sadler JE. von Willebrand factor. J Biol Chem 1991;266:22777.
2. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981;57:1140.
3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578.
4. Mannucci PM, Lombardi R, Lattuada A, et al. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989;73:1586.
5. Moake JL. von Willebrand factor in the pathophysiology of thrombotic trombocytopenic purpura. Clin Lab Sci 1998;11:362.
6. Sadler J. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520.
7. Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand's disease: A concise review. Am J Hematol 1997;54:139.
8. Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987;76:1043.
9. Lopes AA, Maeda NY, Bydlowski SP. Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension. Am J Med 1998;105:21.
10. Veyradier A, Nishikubo T, Humbert M, et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 2000;102:2460.
11. Lopes AAB, Maeda NY, Ebaid M, et al. Effect of intentional hemodilution on platelet survival in secondary pulmonary hypertension. Chest 1989;95:1207.
12. Lopes AAB, Maeda NY. Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur Respir J 1995;8:530.
13. Friedman R, Mears G, Barst R. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96:2782.
14. Pareti FI, Lattuada A, Bressi C, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000;102:1290.
15. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and required calcium ion. Blood 1996;87:4235.
16. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996;88:2939.
17. Dent JA, Berkowitz SD, Ware J, et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990;87:6306.
18. Goto S, Salomon DR, Ikeda Y, et al. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995;270:23352.
19. Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980;302:1047.
20. Ruggeri ZM, Mannucci PM, Lombardi R, et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982;59:1272.
21. Zimmerman TS, Dent JA, Ruggeri ZM, et al. Subunit composition of plasma von Willebrand factor: Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID and IIE). J Clin Invest 1986;77:947.
22. De Marco K, Mazzucato M, De Roia D, et al. Distinct abnormalities in the interaction of purified IIA and IIB von Willebrand factor with the two platelet binding sites GP Ib-IX and GP IIb-IIIa. J Clin Invest 1990;86:785.
23. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: Initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000;1497:1.
24. Tsai H-M, Nagel RL, Hatcher VB, et al. Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun 1989;158:980.
25. Blann AD, Seigneur M, Adams RA, et al. Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Eur J Vasc Endovasc Surg 1996;12:218.
26. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 1996;97:493.
27. Goerge T, Niemeyer A, Rogge P, et al. Secretion pores in human endothelial cells during acute hypoxia. J Membr Biol 2002;187:203.
28. Vongpatanasin W, Brickner E, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128:745.
29. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984;70:580.
30. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356.
31. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coag Fibrinolysis 1998;9:107.
32. Herve P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001;22:451.
33. Lopes AAB, Maeda NY, Almeida A, et al. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology 1993;44:701.
34. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249.
35. Eddahibi S, Humbert M, Sediame S, et al. Imbalance between platelet VEGF and PDGF in pulmonary hypertension, effect of prostacyclin therapy. Am J Respir Crit Care Med 2000;162:1493.